Adverse renal effects of anti‐inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors

Abstract. Gambaro G, Perazella MA (Division of Nephrology, University Hospital, Padua, Italy; and Section of Nephrology, Yale University, New Haven, CT, USA). Adverse renal effects of anti‐inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors (Review). J Intern Med 2003; 253: 643–652.

[1]  M. Perretti,et al.  Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. , 2003, Biochemical pharmacology.

[2]  Roger H Jones.  Efficacy and safety of COX 2 inhibitors , 2002, BMJ : British Medical Journal.

[3]  G. Thornicroft,et al.  The global response to mental illness , 2002, BMJ : British Medical Journal.

[4]  A. Kurtz,et al.  Cyclo‐oxygenase‐2 inhibition increases blood pressure in rats , 2002, British journal of pharmacology.

[5]  K. Brune,et al.  Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet , 2002, Clinical pharmacology and therapeutics.

[6]  A. Whelton,et al.  Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. , 2002, Clinical therapeutics.

[7]  D. Zamir,et al.  The different patterns of blood pressure elevation by rofecoxib and nabumetone , 2002, Journal of Human Hypertension.

[8]  C. Nzerue,et al.  Celecoxib-induced acute interstitial nephritis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  D. B. Rodgers,et al.  A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273] , 2002, BMC family practice.

[10]  M. Armoni,et al.  Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. , 2002, The Journal of emergency medicine.

[11]  W. White,et al.  Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors , 2002, Hypertension.

[12]  R. Bing,et al.  Nitric Oxide, Anti-Inflammatory Drugs on Renal Prostaglandins and Cyclooxygenase-2 , 2002, Hypertension.

[13]  R. Bing,et al.  Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? , 2002, Journal of the American College of Cardiology.

[14]  Paul Wallace,et al.  Design and performance of a multi-centre randomised controlled trial and economic evaluation of joint tele-consultations [ISRCTN54264250] , 2002, BMC family practice.

[15]  T. Schnitzer,et al.  Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. , 2002, JAMA.

[16]  J. Bolognese,et al.  A Comparison of Adverse Renovascular Experiences Among Osteoarthritis Patients Treated with Rofecoxib and Comparator Non-selective Non-steroidal Anti-inflammatory Agents , 2002, Current medical research and opinion.

[17]  C. Clish,et al.  Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase. , 2001, Biochemical and biophysical research communications.

[18]  B. Krämer,et al.  Inhibition of COX-2 counteracts the effects of diuretics in rats. , 2001, Kidney international.

[19]  T. Hishinuma,et al.  Difference in urinary 11-dehydro TXB2 and LTE4 excretion in patients with rheumatoid arthritis. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[20]  F. Rodríguez,et al.  Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. , 2001, American journal of physiology. Renal physiology.

[21]  M. Perazella,et al.  Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. , 2001, The American journal of medicine.

[22]  R. Poduri,et al.  Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin-1 in SHR. , 2001, American journal of physiology. Heart and circulatory physiology.

[23]  J. L. Rocha,et al.  Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib , 2001, The Lancet.

[24]  S. Laufer,et al.  Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. , 2001, Pharmacological research.

[25]  P. Ambühl,et al.  Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion. , 2001, Swiss medical weekly.

[26]  A. Whelton,et al.  Cyclooxygenase-2–Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients , 2001, American journal of therapeutics.

[27]  M. Breyer,et al.  Cyclooxygenase 2 and the kidney , 2001, Current opinion in nephrology and hypertension.

[28]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[29]  S. Swan,et al.  Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet , 2000, Annals of Internal Medicine.

[30]  P. Isakson,et al.  Effects of celecoxib and naproxen on renal function in the elderly. , 2000, Archives of internal medicine.

[31]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[32]  J. Wallace,et al.  Selective cyclo‐oxygenase‐2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence , 2000, British journal of pharmacology.

[33]  J. Kaye,et al.  Apolipoprotein E ε4 Is Associated with Neuronal Loss in the Substantia nigra in Alzheimer’s Disease , 1999, Dementia and Geriatric Cognitive Disorders.

[34]  J. Schnermann,et al.  Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. , 1999, The American journal of physiology.

[35]  O. Laneuville,et al.  NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line. , 1999, Journal of the American Society of Nephrology : JASN.

[36]  B. Connolly,et al.  Immunolocalization of cyclooxygenase‐2 in the macula densa of human elderly , 1999, FEBS letters.

[37]  J. Mcgiff,et al.  Cyclooxygenase-2 expression and function in the medullary thick ascending limb. , 1999, American journal of physiology. Renal physiology.

[38]  M. Burnier,et al.  Renal effects of selective cyclooxygenase‐2 inhibition in normotensive salt‐depleted subjects , 1999, Clinical pharmacology and therapeutics.

[39]  A. Whelton.  Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. , 1999, The American journal of medicine.

[40]  J. Masferrer,et al.  Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. , 1999, Gastroenterology.

[41]  G. FitzGerald,et al.  Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.

[42]  J. Wallace,et al.  Limited anti‐inflammatory efficacy of cyclo‐oxygenase‐2 inhibition in carrageenan‐airpouch inflammation , 1999, British journal of pharmacology.

[43]  Tianxin Yang,et al.  Regulation of cyclooxygenase expression in the kidney by dietary salt intake. , 1998, American journal of physiology. Renal physiology.

[44]  M. Vasseur,et al.  Direct inhibitory effect of CCCP on the Cl--H+ symporter of the guinea pig ileal brush-border membrane. , 1998, American journal of physiology. Cell physiology.

[45]  J. Masferrer,et al.  Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. , 1997, Hypertension.

[46]  H. Seyberth,et al.  Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. , 1997, The American journal of physiology.

[47]  R. O. Day,et al.  Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. , 1996, Journal of human hypertension.

[48]  C. Nickerson-Nutter,et al.  The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. , 1996, Arthritis and rheumatism.

[49]  T. Lee,et al.  The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. , 1995, American journal of respiratory and critical care medicine.

[50]  C. F. Richards.  Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta analysis , 1995 .

[51]  S. Laufer,et al.  General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3- dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals. , 1995, Arzneimittel-Forschung.

[52]  H. Jacobson,et al.  Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. , 1994, The Journal of clinical investigation.

[53]  R. Day,et al.  Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis , 1994, Annals of Internal Medicine.

[54]  T. Kita,et al.  The role of peptide leukotrienes in renal failure induced by a tourniquet. , 1994, Forensic science international.

[55]  D. Felson,et al.  A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. , 1993, Archives of internal medicine.

[56]  E. Gulbins,et al.  Cysteinyl leukotriene actions on the microcirculation of the normal and split hydronephrotic rat kidney , 1991, European journal of clinical investigation.

[57]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[58]  M. Yaron,et al.  Nonsteroidal anti-inflammatory drugs, and hypertension. , 1988, Annals of internal medicine.

[59]  L. Wilkins.  Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5-Year findings of the hypertension detection and follow-up program. , 1984, Hypertension.

[60]  S. Brodsky,et al.  Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure. , 2001, American journal of physiology. Renal physiology.

[61]  A. Hartner,et al.  Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. , 1998, Hypertension.

[62]  P. D. de Leeuw.  Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. , 1996, Drugs.